Identification of CYP2C9*2 Allele in HepG2 Cell Line

Overview

Journal Int J Gastrointest Cancer

Date 2007 Sep 11

PMID 17827526

Citations 2

Authors

Jiezhong Chen

Kenneth Raymond

Affiliations

Soon will be listed here.

Abstract

Background: Hepatoma is caused by many factors including alcohol, chemicals, viral infection, and chronic inflammation. Cytochrome P450 polymorphism plays an important role in its pathogenesis. CYP2D6, CYP2E1, and CYP1A1 have been identified to be related with hepatic carcinogenesis and tumor size and stage. However, no studies have been performed on CYP2C9, a major CYP in the liver and hepatoma.

Aim Of The Study: To identify if there is polymorphism of CYP2C9 in a HepG2 cell line.

Methods: A pair of primers was used to clone CYP2C9 exon 3 region and subsequently sequenced. The sequence was compared to normal CYP2C9 for identification of any mutation.

Results: A point mutation was identified. It was located in the amino acid number 144 of CYP2C9 protein with the change of normal amino acid arginine into cysteine, which is the same as identified in poor metabolism patients as homozygous CYP2C9*2.

Conclusions: There is a mutation (CYP2C9*2/ CYP2C9*2) in a HepG2 cell line. Thus, polymorphism of CYP2C9 may also be involved in the carcinogenesis of hepatoma as CYPs2D6 and 2E1.

Citing Articles

Liver three-dimensional cellular models for high-throughput chemical testing.

Yang S, Ooka M, Margolis R, Xia M Cell Rep Methods. 2023; 3(3):100432.

PMID: 37056374 PMC: 10088249. DOI: 10.1016/j.crmeth.2023.100432.

Bayesian penalized cumulative logit model for high-dimensional data with an ordinal response.

Zhang Y, Archer K Stat Med. 2020; 40(6):1453-1481.

PMID: 33336826 PMC: 9153983. DOI: 10.1002/sim.8851.

References

Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A, Pelkonen O . Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review. Gene. 1995; 159(1):113-21. DOI: 10.1016/0378-1119(94)00448-2. View

Russo I, Russo J . Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia. 2000; 3(1):49-61. DOI: 10.1023/a:1018770218022. View

Nelson D, Koymans L, Kamataki T, Stegeman J, Feyereisen R, Waxman D . P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996; 6(1):1-42. DOI: 10.1097/00008571-199602000-00002. View

Silvestri L, Sonzogni L, De Silvestri A, Gritti C, Foti L, Zavaglia C . CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer. 2003; 104(3):310-7. DOI: 10.1002/ijc.10937. View

De Maria N, Manno M, Villa E . Sex hormones and liver cancer. Mol Cell Endocrinol. 2002; 193(1-2):59-63. DOI: 10.1016/s0303-7207(02)00096-5. View

Tai G, Farin F, Rieder M, Dreisbach A, Veenstra D, Verlinde C . In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics. 2005; 15(7):475-81. DOI: 10.1097/01.fpc.0000162005.80857.98. View

Chao Y, Young T, Chang W, Tang H, Hsu C . An investigation of whether polymorphisms of cytochrome P4502E1 are genetic markers of susceptibility to alcoholic end-stage organ damage in a Chinese population. Hepatology. 1995; 22(5):1409-14. View

Scheers I, Bachy V, Stephenne X, Sokal E . Risk of hepatocellular carcinoma in liver mitochondrial respiratory chain disorders. J Pediatr. 2005; 146(3):414-7. DOI: 10.1016/j.jpeds.2004.10.023. View

Veenstra D, Blough D, Higashi M, Farin F, Srinouanprachan S, Rieder M . CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther. 2005; 77(5):353-64. DOI: 10.1016/j.clpt.2005.01.019. View

10.

Murray C, Lopez A . Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997; 349(9061):1269-76. DOI: 10.1016/S0140-6736(96)07493-4. View

11.

Chen J, Robertson G, Field J, Liddle C, Farrell G . Effects of bile duct ligation on hepatic expression of female-specific CYP2C12 in male and female rats. Hepatology. 1998; 28(3):624-30. DOI: 10.1002/hep.510280304. View

12.

Rettie A, Wienkers L, Gonzalez F, TRAGER W, Korzekwa K . Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994; 4(1):39-42. DOI: 10.1097/00008571-199402000-00005. View

13.

Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J . Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol. 2001; 96(4):1160-3. DOI: 10.1111/j.1572-0241.2001.03695.x. View

14.

Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F . Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos. 2005; 34(1):75-83. DOI: 10.1124/dmd.105.006759. View

15.

Kowdley K . Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1):S79-86. DOI: 10.1016/j.gastro.2004.09.019. View

16.

Yu M, Chiu Y, Yang S, Santella R, Chern H, Liaw Y . Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Br J Cancer. 1999; 80(3-4):598-603. PMC: 2362308. DOI: 10.1038/sj.bjc.6690397. View

17.

King B, Khan T, Aithal G, Kamali F, Daly A . Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004; 14(12):813-22. DOI: 10.1097/00008571-200412000-00004. View

18.

Lee A, Cai M, Thomas P, Conney A, Zhu B . Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003; 144(8):3382-98. DOI: 10.1210/en.2003-0192. View

19.

Werck-Reichhart D, Feyereisen R . Cytochromes P450: a success story. Genome Biol. 2001; 1(6):REVIEWS3003. PMC: 138896. DOI: 10.1186/gb-2000-1-6-reviews3003. View

20.

McGehee Jr R, Ronis M, Cowherd R, Ingelman-Sundberg M, Badger T . Characterization of cytochrome P450 2E1 induction in a rat hepatoma FGC-4 cell model by ethanol. Biochem Pharmacol. 1994; 48(9):1823-33. DOI: 10.1016/0006-2952(94)90469-3. View